Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1995 Sep;69(9):5294–5299. doi: 10.1128/jvi.69.9.5294-5299.1995

Mimicry of the immunodominant conformation-dependent antigenic site of hepatitis A virus by motifs selected from synthetic peptide libraries.

S Mattioli 1, L Imberti 1, R Stellini 1, D Primi 1
PMCID: PMC189366  PMID: 7543581

Abstract

Hepatitis A virus (HAV) is a positive-strand RNA virus with a genome length of approximately 7,480 nucleotides. Although HAV morphogenesis is thought to be similar to that of poliovirus, the prototype picornavirus, the complete characterization of the antigenic structure of this virus remains elusive. All the available evidences, however, support the existence, on HAV virions and empty capsids, of an immunodominant neutralization antigenic site which is conformation dependent and whose structure involves residues of both VP1 and VP3 capsid proteins. This particular feature and the difficulty of obtaining high virus yield in tissue cultures make HAV an ideal target for developing synthetic peptides that simulate the structure of its main antigenic determinant. To this end we utilized, in the present work, the divide-couple-recombine approach to generate a random library composed of millions of different hexapeptides. This vast library was screened with a well-characterized anti-HAV monoclonal antibody. By this strategy we identified a peptide that reacted specifically with monoclonal and polyclonal anti-HAV antibodies and, in mice, induced a specific anti-virus immune response. Furthermore, the peptide could also be used in an enzyme-linked immunosorbent assay for revealing a primary immunoglobulin M immune response in sera of acutely infected human patients. Interestingly, no sequence homology was found between the identified peptide and the HAV capsid proteins VP1 and VP3. Collectively, these data represent an additional important paradigm of a mimotope capable of mimicking an antigenic determinant with unknown tertiary structure.

Full Text

The Full Text of this article is available as a PDF (286.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binn L. N., Lemon S. M., Marchwicki R. H., Redfield R. R., Gates N. L., Bancroft W. H. Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol. 1984 Jul;20(1):28–33. doi: 10.1128/jcm.20.1.28-33.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brown E. A., Jansen R. W., Lemon S. M. Characterization of a simian hepatitis A virus (HAV): antigenic and genetic comparison with human HAV. J Virol. 1989 Nov;63(11):4932–4937. doi: 10.1128/jvi.63.11.4932-4937.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dyson H. J., Sayre J. R., Merutka G., Shin H. C., Lerner R. A., Wright P. E. Folding of peptide fragments comprising the complete sequence of proteins. Models for initiation of protein folding. II. Plastocyanin. J Mol Biol. 1992 Aug 5;226(3):819–835. doi: 10.1016/0022-2836(92)90634-v. [DOI] [PubMed] [Google Scholar]
  4. Emini E. A., Hughes J. V., Perlow D. S., Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985 Sep;55(3):836–839. doi: 10.1128/jvi.55.3.836-839.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Geysen H. M., Rodda S. J., Mason T. J., Tribbick G., Schoofs P. G. Strategies for epitope analysis using peptide synthesis. J Immunol Methods. 1987 Sep 24;102(2):259–274. doi: 10.1016/0022-1759(87)90085-8. [DOI] [PubMed] [Google Scholar]
  6. Houghten R. A., Pinilla C., Blondelle S. E., Appel J. R., Dooley C. T., Cuervo J. H. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature. 1991 Nov 7;354(6348):84–86. doi: 10.1038/354084a0. [DOI] [PubMed] [Google Scholar]
  7. Kaiser E., Colescott R. L., Bossinger C. D., Cook P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 1970 Apr;34(2):595–598. doi: 10.1016/0003-2697(70)90146-6. [DOI] [PubMed] [Google Scholar]
  8. Kurane I., Binn L. N., Bancroft W. H., Ennis F. A. Human lymphocyte responses to hepatitis A virus-infected cells: interferon production and lysis of infected cells. J Immunol. 1985 Sep;135(3):2140–2144. [PubMed] [Google Scholar]
  9. Lam K. S., Salmon S. E., Hersh E. M., Hruby V. J., Kazmierski W. M., Knapp R. J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature. 1991 Nov 7;354(6348):82–84. doi: 10.1038/354082a0. [DOI] [PubMed] [Google Scholar]
  10. Lang E., Szendrei G. I., Lee V. M., Otvos L., Jr Spectroscopic evidence that monoclonal antibodies recognize the dominant conformation of medium-sized synthetic peptides. J Immunol Methods. 1994 Mar 29;170(1):103–115. doi: 10.1016/0022-1759(94)90250-x. [DOI] [PubMed] [Google Scholar]
  11. Lemon S. M., Binn L. N., Marchwicki R., Murphy P. C., Ping L. H., Jansen R. W., Asher L. V., Stapleton J. T., Taylor D. G., LeDuc J. W. In vivo replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus. J Infect Dis. 1990 Jan;161(1):7–13. doi: 10.1093/infdis/161.1.7. [DOI] [PubMed] [Google Scholar]
  12. Lemon S. M., Binn L. N. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis. 1983 Dec;148(6):1033–1039. doi: 10.1093/infdis/148.6.1033. [DOI] [PubMed] [Google Scholar]
  13. Lemon S. M., Chao S. F., Jansen R. W., Binn L. N., LeDuc J. W. Genomic heterogeneity among human and nonhuman strains of hepatitis A virus. J Virol. 1987 Mar;61(3):735–742. doi: 10.1128/jvi.61.3.735-742.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lemon S. M. Type A viral hepatitis. New developments in an old disease. N Engl J Med. 1985 Oct 24;313(17):1059–1067. doi: 10.1056/NEJM198510243131706. [DOI] [PubMed] [Google Scholar]
  15. MacGregor A., Kornitschuk M., Hurrell J. G., Lehmann N. I., Coulepis A. G., Locarnini S. A., Gust I. D. Monoclonal antibodies against hepatitis A virus. J Clin Microbiol. 1983 Nov;18(5):1237–1243. doi: 10.1128/jcm.18.5.1237-1243.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Maier K., Gabriel P., Koscielniak E., Stierhof Y. D., Wiedmann K. H., Flehmig B., Vallbracht A. Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J Virol. 1988 Oct;62(10):3756–3763. doi: 10.1128/jvi.62.10.3756-3763.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nakane P. K., Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem. 1974 Dec;22(12):1084–1091. doi: 10.1177/22.12.1084. [DOI] [PubMed] [Google Scholar]
  18. Ping L. H., Jansen R. W., Stapleton J. T., Cohen J. I., Lemon S. M. Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8281–8285. doi: 10.1073/pnas.85.21.8281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ping L. H., Lemon S. M. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol. 1992 Apr;66(4):2208–2216. doi: 10.1128/jvi.66.4.2208-2216.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Scott J. K., Smith G. P. Searching for peptide ligands with an epitope library. Science. 1990 Jul 27;249(4967):386–390. doi: 10.1126/science.1696028. [DOI] [PubMed] [Google Scholar]
  21. Siegl G., Frösner G. G., Gauss-Müller V., Tratschin J. D., Deinhardt F. The physicochemical properties of infectious hepatitis A virions. J Gen Virol. 1981 Dec;57(Pt 2):331–341. doi: 10.1099/0022-1317-57-2-331. [DOI] [PubMed] [Google Scholar]
  22. Stapleton J. T., Jansen R., Lemon S. M. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology. 1985 Sep;89(3):637–642. doi: 10.1016/0016-5085(85)90462-7. [DOI] [PubMed] [Google Scholar]
  23. Stapleton J. T., Lemon S. M. Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. J Virol. 1987 Feb;61(2):491–498. doi: 10.1128/jvi.61.2.491-498.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Stapleton J. T., Raina V., Winokur P. L., Walters K., Klinzman D., Rosen E., McLinden J. H. Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles. J Virol. 1993 Feb;67(2):1080–1085. doi: 10.1128/jvi.67.2.1080-1085.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tam J. P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5409–5413. doi: 10.1073/pnas.85.15.5409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vallbracht A., Maier K., Stierhof Y. D., Wiedmann K. H., Flehmig B., Fleischer B. Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis. 1989 Aug;160(2):209–217. doi: 10.1093/infdis/160.2.209. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES